The Lupus Research Alliance today announced a collaboration between its newly formed affiliate, Lupus Therapeutics, and the pharmaceutical company,?BMS, to test a novel investigational drug, BMS-986165
Janssen Pharmaceuticals has?teamed up?with?Bristol-Myers Squibb?to drive BMS-986177, a Factor XIa (FXIa) inhibitor, into Phase II development for the study of secondary stroke prevention and major thrombotic conditions.
PD-L1 is involved in the body’s immune response to cancer and nivolumab demonstrates better effectiveness in patients who have more PD-L1 protein on their cancer cells.